Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 783 of 5804
-
New combo therapy aims to tame heart sarcoidosis with fewer side effects
Disease control Recruiting nowProspective randomized controlled trial comparing low dose Prednisone(or Prednisolone)/Methotrexate combination to standard dose Prednisone(or Prednisolone) in patients diagnosed with acute active clinically manifest cardiac sarcoidosis and not yet treated. The Investigators hyp…
Phase: PHASE3 • Sponsor: Ottawa Heart Institute Research Corporation • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New hope for rare genetic cancers? drug targets POLE/POLD1 mutations
Disease control Recruiting nowThe purpose of this study is to evaluate the response of toripalimab (JS001), a PD1 antibody, in participants with POLE or POLD-mutated and non microsatellite instability (non-MSI-H) advanced solid cancers.
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New combo aims to stop breast cancer return after failed chemo
Disease control OngoingThis study will enroll patients who received neoadjuvant therapy for TNBC prior to surgery and did not get pCR. Given the relatively poor prognosis for these patients, this population is considered novel therapeutic as adjuvant treatment. Currently, capecitabine monotherapy could…
Phase: PHASE2 • Sponsor: National Cancer Center, Korea • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug shows promise in reducing bleeding for hemophilia patients
Disease control OngoingPrimary Objective: To characterize the long-term safety and tolerability of fitusiran Secondary Objectives: * To characterize the efficacy and long-term efficacy of fitusiran as assessed by the frequency of: * Bleeding episodes * Spontaneous bleeding episodes * Joint bl…
Phase: PHASE3 • Sponsor: Genzyme, a Sanofi Company • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New drug cocktail aims to outsmart resistant lung cancer
Disease control OngoingThis study (the SAVANNAH study) will investigate the efficacy of osimertinib in combination with savolitinib in patients with EGFRm+ and MET+, locally advanced or metastatic NSCLC who have progressed following treatment with osimertinib
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for rare kidney cancer: drug combo shows promise
Disease control OngoingThis phase II trial studies how well axitinib and nivolumab work in treating patients with TFE/translocation renal cell carcinoma that cannot be removed by surgery (unresectable) or has spread to other places in the body (metastatic). Axitinib may stop the growth of tumor cells b…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Intense lifestyle overhaul shows promise for new diabetes patients
Disease control OngoingIt is a multicenter, open-label, parallel-group, randomized controlled clinical trial, which is designed to enroll newly diagnosed type 2 diabetes patients with overweight or obesity. The patients are randomized to an intensive diet intervention (intermittent very-low -calorie di…
Phase: NA • Sponsor: Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New drug shows promise for stubborn cancers
Disease control OngoingGSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refrac…
Phase: PHASE2 • Sponsor: Actuate Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New transplant approach offers hope for sickle cell patients without a perfect donor match
Disease control OngoingBlood stem cells can produce red blood cells (which carry oxygen), white blood cells of the immune system (which fight infections) and platelets (which help the blood clot). Patients with sickle cell disease produce abnormal red blood cells. A blood stem cell transplant from a d…
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
HIV-Positive livers safe for HIV-Positive patients? landmark trial results
Disease control CompletedThe primary objective of this study is to determine if an HIV-infected donor liver (HIVD+) transplant is safe with regards to major transplant-related and HIV-related complications
Phase: NA • Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Cord blood stem cells boost recovery in High-Risk cancer patients
Disease control OngoingThis is an single arm, open label, interventional phase II trial evaluating the efficacy of umbilical cord blood (UCB) hematopoietic stem and progenitor cells (HSPC) expanded in culture with stimulatory cytokines (SCF, Flt-3L, IL-6 and thromopoietin) on lympho-hematopoietic recov…
Phase: PHASE2 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Syringe exchange clinics offer new hope for opioid addiction treatment
Disease control CompletedThis trial will recruit syringe exchange participants with opioid use disorder in New York City and test whether starting buprenorphine treatment at the syringe exchange program is more effective than referral to a community health center for buprenorphine treatment.
Phase: PHASE2 • Sponsor: Montefiore Medical Center • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Immunotherapy drug nivolumab takes on rare blood cancer in kids and adults
Disease control OngoingProspective, non-randomized, single arm phase II trial with 2 cohorts of ALK+ ALCL treated with nivolumab
Phase: PHASE2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Immunotherapy-Chemo combo shows promise in aggressive lymphoma trial
Disease control OngoingThis phase II trial studies how well nivolumab works with the DA-REPOCH chemotherapy regimen in treating patients with aggressive B-cell non-Hodgkin lymphoma. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body?s immune system attack the cancer, and may…
Phase: PHASE2 • Sponsor: David Bond, MD • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Can a scan replace the needle? ultrasound and MRI put to the test against liver biopsy for fatty liver disease
Diagnosis CompletedNon-alcoholic fatty liver disease (NAFLD) is a highly prevalent condition, and when fatty liver is associated with inflammation and hepatocellular injury (steatohepatitis), it can lead to fibrosis, cirrhosis, liver failure and hepatocellular carcinoma. Liver biopsy is the gold st…
Phase: NA • Sponsor: Azienda USL Reggio Emilia - IRCCS • Aim: Diagnosis
Last updated Jul 26, 2026 00:00 UTC
-
New AI reads CT scans to predict which esophageal cancers vanish after treatment
Diagnosis CompletedThis multicenter, retrospective cohort study reviews the medical records and CT scans of adults with esophageal squamous cell carcinoma (ESCC) who received neoadjuvant immunotherapy plus chemotherapy before surgery at three hospitals in China. The goal is to develop and validate …
Sponsor: Nanjing Medical University • Aim: Diagnosis
Last updated Jun 26, 2026 18:28 UTC
-
Common painkiller may boost lung cancer Drug's power
Disease control CompletedThe third generation epidermal growth factor receptor-tyrosine Kinase Inhibitor(EGFR-TKI) osimertinib has obvious curative effect for EGFR sensitive mutation and T790M mutation(PMID 27959700), but acquired drug resistance will occur. Previous studies show that apoptosis escape ca…
Phase: PHASE2 • Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Robot-Guided surgery plus Clot-Busting drug aims to improve brain bleed recovery
Disease control OngoingSpontaneous cerebral hemorrhage is one of the main causes of death and disability all over the world, accounting for 20%-30% of all cerebrovascular diseases. Minimally invasive surgery of cerebral hemorrhage, especially puncture aspiration, can improve early and long-term neurolo…
Phase: NA • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
AI model could spare diabetes patients from invasive kidney biopsies
Diagnosis CompletedThis multicenter retrospective observational study aims to develop and validate an interpretable machine learning model for differentiating diabetic kidney disease (DKD) from non-diabetic kidney disease (NDKD) in patients with type 2 diabetes mellitus. Clinical, laboratory, and p…
Sponsor: Beijing Tongren Hospital • Aim: Diagnosis
Last updated Jul 01, 2026 00:00 UTC
-
New combo attack on stubborn cancers shows promise in early trial
Disease control OngoingThis phase II trial studies how well nivolumab and temozolomide work in treating patients with small-cell lung cancer that has come back or does not respond to treatment, or neuroendocrine cancer that has spread to other places in the body. Immunotherapy with monoclonal antibodie…
Phase: PHASE2 • Sponsor: Dwight Owen • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC